The Managements of Opharmic are pleased to announce that the Japan Patent Office has granted the patent covering the MeticTouch ocular induction platform technology. Extensively covering the method, design, and applications of the novel drug delivery system, the MeticTouch platform offers exclusive opportunities to its partners by providing non-invasive delivery solutions to therapeutics at all stages of drug discovery.
The granted patent enables our continued efforts in establishing research and commercial partnerships with new and existing pharma companies in Japan. Demonstrating JPO’s recognition of Opharmic’s innovation, the granting of this patent lays a powerful springboard to the launch of our MeticTouch partnership programme.
Click here to learn more about partnering with Opharmic.